LCN2 and urinary bladder cancer: Through inhibiting SPOP-mediated degradation of LATS1, circXRN2 increases its stability. This activates the Hippo signaling pathway, which in turn decreases H3K18 lactylation and lowers LCN2 expression in bladder cancer.